Breast Cancer

Single-agent pembrolizumab produced durable responses in women with metastatic triple-negative breast cancer who have received prior chemotherapy for metastatic disease.
A 9-week course of trastuzumab as adjuvant therapy in women with hormone receptor–positive, early-stage breast cancer can maintain efficacy and reduce toxicity compared with the standard 1-year course of trastuzumab.
Two additional trastuzumab biosimilar agents demonstrate therapeutic equivalence to trastuzumab in women with HER2-positive breast cancer.
The global phase 3 MONARCH 2 trial showed a significant advantage to adding the CDK4/6 inhibitor abemaciclib to fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer.
Pembrolizumab improves response rates in the phase 2 I-SPY 2 trial of women with various subtypes of high-risk breast cancer.
For the first time, a PARP inhibitor used as monotherapy has proved superior to standard chemotherapy in the treatment of women with metastatic breast cancer with a germline BRCA mutation.
Palbociclib may reverse acquired resistance to endocrine therapy in women with hormone receptor‒positive, HER2-negative breast cancer.
An updated analysis of PALOMA-1 shows no significant survival advantage when palbociclib is added to letrozole in women with estrogen receptor–positive breast cancer.
CDK4/CDK6 inhibitors are a promising addition to the armamentarium for the treatment of patients with breast cancer. At the 42nd annual meeting of the Oncology Nursing Society, 2 experts discussed the role of these new drugs, and how to factor them into treatment decisions.

Data suggest that greater than one-fourth of patients with estrogen receptor–positive metastatic breast cancer who are treated with an aromatase inhibitor (AI) will develop a mutation in the ESR1 gene, conferring resistance to the AI. Response after AI failure is poor, leading to a search for better therapeutic options.

Page 5 of 18
Results 41 - 50 of 175